Can you take Caplacizumab with Plasminogen, human?
1 drug interaction and 2 additional warnings found for the following 2 drugs:
- caplacizumab
- plasminogen, human
Drug interactions
Major drug interactions
Major:
caplacizumab plasminogen, human
Applies to: caplacizumab and plasminogen, human
Using plasminogen, human together with caplacizumab may increase the risk of bleeding.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
2 potential interactions Applies to: 2 conditions, including Liver Disease and Coagulation Defects and Disorders.
Coagulation Defects and Disorders
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Coagulation Defects and Disorders.
Caplacizumab increases the risk of bleeding. This risk is increased in patients with underlying coagulopathies (e.g., hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of drugs affecting hemostasis and coagulation. Treatment with caplacizumab should be interrupted if clinically significant bleeding occurs. Caution and close monitoring is advised.
Liver Disease
Moderate:
caplacizumab
Caplacizumab has a moderate potential interaction with Liver Disease.
No formal studies with caplacizumab have been conducted in patients with severe acute or chronic hepatic impairment and no data regarding the use of the drug in these populations are available. Due to a potential increased risk of bleeding, the use of caplacizumab in patients with severe hepatic impairment requires close monitoring.
Report options
More resources
caplacizumab
A total of 166 drugs are known to interact with caplacizumab.
- Caplacizumab is in the drug class platelet aggregation inhibitors.
- Caplacizumab is used to treat Thrombotic Thrombocytopenic Purpura.
plasminogen, human
A total of 77 drugs are known to interact with plasminogen, human.
- Plasminogen, human is in the drug class miscellaneous uncategorized agents.
- Plasminogen, human is used to treat Hypoplasminogenemia.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.